Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Coastal Investment Advisors Inc.

Coastal Investment Advisors Inc. lessened its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 22.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,531 shares of the biopharmaceutical company’s stock after selling 1,606 shares during the quarter. Coastal Investment Advisors Inc.’s holdings in Emergent BioSolutions were worth $496,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of EBS. IFP Advisors Inc lifted its position in shares of Emergent BioSolutions by 604.8% during the 3rd quarter. IFP Advisors Inc now owns 296 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 254 shares during the last quarter. Daiwa Securities Group Inc. purchased a new stake in shares of Emergent BioSolutions during the 3rd quarter worth approximately $31,000. Cutler Group LP lifted its position in shares of Emergent BioSolutions by 300.0% during the 3rd quarter. Cutler Group LP now owns 400 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 300 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of Emergent BioSolutions during the 3rd quarter worth approximately $59,000. Finally, Private Advisor Group LLC purchased a new stake in shares of Emergent BioSolutions during the 2nd quarter worth approximately $99,000. Institutional investors and hedge funds own 73.00% of the company’s stock.

Shares of Emergent BioSolutions stock opened at $107.65 on Thursday. The company has a market cap of $5.71 billion, a P/E ratio of 34.61 and a beta of 1.24. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.30 and a current ratio of 3.20. Emergent BioSolutions Inc. has a one year low of $46.37 and a one year high of $137.61. The firm has a fifty day moving average of $89.92 and a two-hundred day moving average of $98.37.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings data on Wednesday, November 11th. The biopharmaceutical company reported $2.19 EPS for the quarter, topping the Zacks’ consensus estimate of $2.12 by $0.07. The company had revenue of $385.20 million during the quarter, compared to the consensus estimate of $438.51 million. Emergent BioSolutions had a net margin of 12.50% and a return on equity of 26.68%. Emergent BioSolutions’s quarterly revenue was up 23.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.24 EPS. As a group, equities analysts predict that Emergent BioSolutions Inc. will post 6.87 earnings per share for the current year.

In other news, Chairman Fuad El-Hibri sold 20,000 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $90.44, for a total transaction of $1,808,800.00. Following the transaction, the chairman now directly owns 1,143,988 shares of the company’s stock, valued at approximately $103,462,274.72. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 14.10% of the company’s stock.

Several brokerages have recently weighed in on EBS. Wells Fargo & Company downgraded shares of Emergent BioSolutions from an “overweight” rating to an “equal weight” rating and set a $110.00 price objective for the company. in a research report on Friday, January 8th. BidaskClub downgraded shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Tuesday, December 29th. Zacks Investment Research downgraded shares of Emergent BioSolutions from a “strong-buy” rating to a “hold” rating and set a $92.00 price target for the company. in a research report on Wednesday, November 11th. Finally, ValuEngine downgraded shares of Emergent BioSolutions from a “sell” rating to a “strong sell” rating in a research report on Monday, November 9th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company. Emergent BioSolutions presently has an average rating of “Hold” and a consensus price target of $95.43.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.

Featured Story: Arbitrage

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent BioSolutions Inc. (NYSE:EBS).

Institutional Ownership by Quarter for Emergent BioSolutions (NYSE:EBS)

Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.